Relapsing B-cell dependent rheumatologic diseases involve overactive B-cells in the immune system, which can lead to joint pain, tissue damage, and repeated disease flare-ups. This group includes conditions such as rheumatoid arthritis and lupus, where symptoms may improve and worsen unpredictably over time. These cycles of relapse can affect mobility, energy levels, and the ability to manage daily activities.

Current treatments primarily focus on suppressing the immune system and reducing flare-ups, though achieving long-term remission can be challenging. Clinical trials are exploring targeted B-cell therapies designed to help prevent relapses, slow disease progression, and improve long-term management outcomes.